OBJECTIVE: This study aimed to estimate incidence, cost per episode of care, and US population burden of cervical intraepithelial neoplasia (CIN). MATERIALS AND METHODS: For women continuously enrolled in a US health plan from January 1, 1999 to December 31, 2004, medical claims were used to identify potential CIN diagnosis. Presence and grade of CIN (CIN 1, CIN 2,3, or no CIN) were verified in medical records for a randomly selected subset (n = 254). Incidence, costs, and population burden were calculated. RESULTS: Annual incidence for CIN 1 and CIN 2,3 was 1.6 and 1.2 per 1,000 women, respectively. Incidence was highest among women aged 21 to 30 years (3.3 and 3.6 per 1,000) and women aged 31 to 40 years (2.9 and 2.7 per 1,000). Costs per episode of care were higher for CIN 2,3 ($1,634 vs $1,084). Estimated annual burden per 1,000 US women was $1,059 for CIN 1 and $1,803 for CIN 2,3. CONCLUSIONS: We estimate that 412,000 women in the United States are diagnosed with CIN annually, with an associated cost of approximately $570 million.
OBJECTIVE: This study aimed to estimate incidence, cost per episode of care, and US population burden of cervical intraepithelial neoplasia (CIN). MATERIALS AND METHODS: For women continuously enrolled in a US health plan from January 1, 1999 to December 31, 2004, medical claims were used to identify potential CIN diagnosis. Presence and grade of CIN (CIN 1, CIN 2,3, or no CIN) were verified in medical records for a randomly selected subset (n = 254). Incidence, costs, and population burden were calculated. RESULTS: Annual incidence for CIN 1 and CIN 2,3 was 1.6 and 1.2 per 1,000 women, respectively. Incidence was highest among women aged 21 to 30 years (3.3 and 3.6 per 1,000) and women aged 31 to 40 years (2.9 and 2.7 per 1,000). Costs per episode of care were higher for CIN 2,3 ($1,634 vs $1,084). Estimated annual burden per 1,000 US women was $1,059 for CIN 1 and $1,803 for CIN 2,3. CONCLUSIONS: We estimate that 412,000 women in the United States are diagnosed with CIN annually, with an associated cost of approximately $570 million.
Authors: Mei-Chin Hsieh; Elizabeth Van Dyne; Christina Lefante; Jean A Shapiro; Paran Pordell; Mary Anne Lynch; Natalie Gomez; Brent Mumphrey; Lauren Maniscalco; Rachna Jetly-Shridhar; Mona Saraiya; Xiao-Cheng Wu Journal: J Registry Manag Date: 2019
Authors: Shayna N Conner; Heather A Frey; Alison G Cahill; George A Macones; Graham A Colditz; Methodius G Tuuli Journal: Obstet Gynecol Date: 2014-04 Impact factor: 7.661
Authors: Harrell W Chesson; Lauri E Markowitz; Susan Hariri; Donatus U Ekwueme; Mona Saraiya Journal: Hum Vaccin Immunother Date: 2016-02-18 Impact factor: 3.452
Authors: Jean-François Laprise; Harrell W Chesson; Lauri E Markowitz; Mélanie Drolet; Dave Martin; Élodie Bénard; Marc Brisson Journal: Ann Intern Med Date: 2019-12-10 Impact factor: 25.391
Authors: Harrell W Chesson; Elaine W Flagg; Laura Koutsky; Katherine Hsu; Elizabeth R Unger; Judith C Shlay; Peter Kerndt; Khalil G Ghanem; Jonathan M Zenilman; Michael Hagensee; Hillard Weinstock; S Deblina Datta Journal: Vaccine Date: 2013-05-10 Impact factor: 3.641